Post by
bfw on May 24, 2021 8:59am
NGM NASH drug bites the dust
These results are certainly disappointing, particularly given the dire unmet need in this patient population. The lack of significant fibrosis improvement was unexpected given the consistency of histology findings previously seen with aldafermin in our adaptive four-cohort Phase 2 study,” said David J. Woodhouse, Ph.D., Chief Executive Officer at NGM. “However, in line with the data from that study, ALPINE 2/3 achieved statistical significance on multiple non-invasive measures of NASH at the two higher doses. That said, given the failure to meet the primary endpoint, we have decided to shift resources that had previously been reserved for a Phase 3 F2/F3 NASH development program toward advancing our other programs.”
Comment by
SPCEO1 on May 24, 2021 9:08am
MDGL's CFO told me a while back that he viewed NGM as the biggest threat to them in NASH. So, I am surprised to see them fail so completely. It is both a positive and a negative for TH. Positive in that another NASH competitor bites the dust, negative in that it makes spending a huge sum of money on a phase III test seem even more daunting.
Comment by
Wino115 on May 24, 2021 9:52am
I guess you could add Viking to the Thyroid agonist race too. SPCEO, any insights from the LIver Therapy analyst?
Comment by
SPCEO1 on May 24, 2021 10:24am
She thinks NGM made a mistake by making fibrosis their endpoint. Frankly, I am not sure what to make of her analysis generally as she often says she has propietary info that she cannot share.
Comment by
qwerty22 on May 24, 2021 10:55am
You sort of have to applaud the CEO here. They could have released this data Friday evening and spun things more, maybe been less emphatic about killing the program. Instead they lay it out plain and simple, time to move on. They have a backup cancer program, sound familiar?
Comment by
bfw on May 24, 2021 11:06am
thought the same thing. Except, their market cap was over $2 Billion US prior to this announcement. bfw
Comment by
jeffm34 on May 24, 2021 11:47am
Their 3 mg dose resulted in a 59% decrease in liver fat. Despite this, it did not produce a 1 stage or more improvement of fibrosis. How will TH's results be any different unless the issue comes down to trial design?
Comment by
BlitzBuuckeyeoh on May 24, 2021 11:57am
Seems to me slowing or stopping progression would be beneficial.